Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Símbolo de cotizaciónTIVC
Nombre de la empresaTivic Health Systems Inc
Fecha de salida a bolsaNov 11, 2021
Director ejecutivoErnst (Jennifer)
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 11
Dirección47685 Lakeview Blvd
CiudadFREMONT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94538
Teléfono18882766888
Sitio Webhttps://tivichealth.com/
Símbolo de cotizaciónTIVC
Fecha de salida a bolsaNov 11, 2021
Director ejecutivoErnst (Jennifer)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos